Spark Hope for Brendan, Jr.

Deb and Brendan Foley have a very personal reason for supporting NETRF and working to recruit more families to do the same. Their son was diagnosed with a NET at just 15 years old.

Grateful for the innovative NET research underway around the globe funded by NETRF, the Foleys have made an investment to keep NET research moving forward. “There is tremendous potential for all of us to make a difference and Deb and I are on board to help expand the reach and support of NETRF, says Brendan, a new member of the NETRF Board of Directors.”

“We are truly inspired by the Foley family’s philanthropy and their desire to help find cures and improved treatments,” said Elyse Gellerman, NETRF Chief Executive Officer.

Hear about the Foley family’s journey and why they Spark Hope for the future. (MORE)

Research

Combining Benefits of Targeted Therapy and Chemotherapy

A new NETRF-funded researcher will explore a novel approach to attach a toxic payload of a cancer drug to a monoclonal antibody to target cancer cells without harming healthy cells. The approach is called an antibody-drug conjugate. (MORE)

Searching for the Cause of SmalI Intestine NETs

Much about a carcinoid cancer cell remains a mystery. For that reason, NETRF funds research to understand how and why a neuroendocrine cancer cell comes to be. An Accelerator Award team hopes to find the cell of origin responsible for making a healthy cell a cancer cell. (MORE)

NET researchers rely on private funding. Few federal dollars are available for rare diseases. It also takes seed funding to develop projects to the point where they can compete for a government or institutional grant. Learn where and how your dollars make a difference. (MORE)

Get Involved

DC Walk for Carcinoid Cancer Exceeds Goals

Despite a gusty, northerly breeze and temperatures in the high 30s, 177 walkers, 18 volunteers, and many family dogs turned out for the first-ever DC Walk for Carcinoid Cancer on Saturday, November 10th, World NET Cancer Awareness Day in Arlington, VA. (MORE)

The Busiest Time of Year

With the end of 2018 just weeks away, life has moved into high-gear with the holidays fast approaching and the many tasks that come with making the holidays special for family and friends. Along with holiday festivities, many of us are considering our year-end charitable gifts. Here at NETRF, our year-end is typically the busiest time of year for receiving donations, and we are fortunate that so many include us when making their year-end gifts. We are preparing for a fun #GivingTuesday on November 27th and other year-end activities to entice our supporters, old and new, to once again give to NET research and we continue to fund the most promising and innovative NET science around the globe. (MORE)

Education & Advocacy

Inherited Risk Factors:

Can NETs be passed down?

Most neuroendocrine tumors (NETs) appear to be sporadic—people do not have a family history or an inherited change in DNA that increases their risk for NETs.
But a percentage of NETs is associated with inherited risk factors. Learn about the genetic risk factors associated with neuroendocrine cancer and what questions to ask your doctor about genetic testing.(MORE)

A Better Way to Image NETs? The Gallium-68 PET/CT Scan

If you’ve ever been tested for eyeglasses, you know how one lens can create grainy, foggy images and the next crisp, clear letters. That’s the kind of difference you can see between:

Image A: Octreotide-based scan, and
Image B: PET/CT scan using Gallium-68 dotatate.

Approved in 2016 by U.S. FDA, Gallium-68 PET/CT scans are seen as a new standard in neuroendocrine cancer care, but access remains an issue. Learn how this new scan is better. Who may benefit most from it... And why the Gallium-68 PET/CT scan is so hard to find... (MORE)

A Month of Awareness

Pancreatic neuroendocrine cancer vs. pancreatic adenocarcinoma

November is recognized as Pancreatic Cancer Awareness Month. The 10th of November also marks World NET Cancer Awareness Day. So it begs the question—what is the difference between these two cancer types affecting the same organ?

Learn about the roles of the endocrine and exocrine systems in your pancreas and how each is related to a different type of cancer. (MORE)

Presenters for NYC December 1, 2018 conference on NETs

Experts Share Knowledge on Dec 1st in NY, NY

Lung NETs, PRRT, and surgery are among the topics on the agenda for a full-day free patient and caregiver conference on Saturday, December 1st in New York City co-sponsored by the NET Research Foundation and The Tisch Cancer Institute at Mount Sinai. Don't miss our last patient and caregiver event of the year. Register today. (MORE)

Living Healthy with NETs

Amanda Woods and Maigenete Mengesha, Wellness House, Chicago, tag team on a presentation about living well with NETs. Amanda offers insights into the role exercise can play to alleviate cancer-related fatigue. She discusses guidelines for exercising with cancer and addresses some of the most common obstacles. Maigenete talks about three ways to improve your mental health while living with NETS. (MORE)

In Memory

With great sadness, we note the passing of two friends and members of the NETRF community.

David Bingham, leader of the Houston NET support group, died on October 14, 2018, 12 years after his NET diagnosis. David helped many NET patients by being a resource and leading through example, by living a full life with family, friends, golf, travel, sports, and grilling for Sunday family dinners. We were fortunate to work with David when we planned our 2018 Houston NET Patient and Caregiver Conference. He was a member of the Patient and Caregiver panel, sharing his advice and positive attitude with the group.

Beth Ripston passed on October 28, 2018, in New York City. Beth served on NETRF’s Audit and Investment Committee, sharing expertise she gained during a successful 33-year career in finance. Beth was kind and caring. She was a member of the Big Apple NET Support group and active as a minister in her church, Marble Collegiate Church.

All of us at NETRF send our sympathies to David’s and Beth’s family and friends. We will miss them.

This eUpdate is sponsored by Entrinsic Health Solutions

DONATE

The mission of the Neuroendocrine Tumor Research Foundation is to fund research to discover cures and more effective treatments for carcinoid, pancreatic, and related neuroendocrine cancers.

NETRF is a 501(c)(3) organization. All contributions are tax-deductible to the extent allowed by law. To learn more,
view our Audited Financial Statements and IRS Form 990.

Manage your preferences | Opt out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.

321 Columbus Avenue, Suite 5R
Boston, MA | 02116 US

This email was sent to .
To continue receiving our emails, add us to your address book.